Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | Sofetabart Mipitecan | Platinum-sensitive ovarian cancer | Phase 3 | Trial Planned | Oral | Oncology |
| Eli Lilly and Company | Retatrutide - (TRANSCEND-T2D 1/2/3) | Type 2 Diabetes | Phase 3 | Ongoing | Subcutaneous | Endocrinology |
| Eli Lilly and Company | Orforglipron | Osteoarthritis pain of the knee and overweight or obesity | Phase 3 | Trial Planned | Oral | Orthopedic |
| Eli Lilly and Company | Zepbound (tirzepatide) - (SURMOUNT-5) | Obesity | Phase 3 | Data Released | Subcutaneous | Endocrinology |
| Eli Lilly and Company | Tibulizumab (LY3090106) | Primary Sjogren's Syndrome | Phase 2/3 | Withdrawn | Intravenous | Immunology |
| Eli Lilly and Company | Trulicity (dulaglutide) - (AWARD-PEDS) | Type 2 diabetes | Phase 3 | Subcutaneous | Endocrinology | |
| Eli Lilly and Company | Torudokimab (ZB-880) | Asthma | Phase 2/3 | Ongoing | Intravenous | Respiratory |
| Eli Lilly and Company | Brenipatide - (RENEW-Bipolar-1) | Major depressive disorder | Phase 3 | Trial Planned | Intranasal | Psychiatric |
